

ANNOUNCEMENT



**EARLY NOTIFICATION
OF DISCONTINUATION**



12 August 2020

Dear Valued Customer

CELESTAMINE® TABLETS & SYRUP

This letter serves as an early notification that **MSD (Pty) Ltd** is in the process of discontinuing **CELESTAMINE® Tablets & Syrup**.

The below **NAPPI** codes apply:

NAPPI CODE	SCHEDULE	DSV CODE	TRADE NAME	PACK SIZE
713066017	S4	150520	CELESTAMINE® Tablets	30s
713058006	S4	150573	CELESTAMINE® Syrup	120 ml

Please note that the current stockholding is the final shipment and will ensure product availability for the next few months only. Once the current stockholding is sold-out, we will send the final notification of discontinuation.

Yours sincerely

Yvette Kilian

Director: Primary Care

011 655 3000 | Email: dpoc_zaf@merck.com

CELESTAMINE®

betamethasone | dexchlorpheniramine maleate

FOR FULL PRESCRIBING INFORMATION REFER TO THE PACKAGE INSERT APPROVED BY THE MEDICINES REGULATORY AUTHORITY



MSD (Pty) Ltd (Reg. No. 1996/003791/07),
Private Bag 3, Halfway House 1685 | Tel: (011) 655-3000
www.msd.co.za

S4 **CELESTAMINE®** Tablets. Each tablet contains 0,25 mg Betamethasone and 2 mg Dexchlorpheniramine maleate. Ref No. G2951 (Act 101/1965). **S4** **CELESTAMINE®** Syrup. Each 5 ml contains 0,25 mg Betamethasone and 2 mg Dexchlorpheniramine maleate. Ref No. G2954 (Act 101/1965).

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A. All rights reserved.
If you no longer wish to receive further e-mails, please [unsubscribe](#) here. ZA-XAB-00003 08/22